MANNHEIM, Germany, May 14, 2025 — Affimed N.V. (Nasdaq: AFMD), an immuno-oncology firm in clinical trials focused on enhancing patients’ innate cancer-fighting abilities, has been notified by Nasdaq that its common shares will be suspended from trading on May 20, 2025. This action aligns with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, leading to the filing of a Form 25 Notification of Delisting with the U.S. Securities Exchange Commission.

The Nasdaq Staff’s decision was influenced by public interest concerns related to Affimed’s insolvency filing in Mannheim, Germany, as well as worries about the equity interests of current security holders and the company’s capacity to maintain Nasdaq listing requirements. Affimed does not plan to appeal this decision.

As previously disclosed, Affimed initiated insolvency proceedings with the local court in Mannheim, Germany, on May 13, 2025.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company focused on restoring patients’ innate ability to combat cancer by harnessing the potential of the innate immune system. The company’s innate cell engagers (ICE^®) offer a targeted method to identify and eliminate various hematologic and solid tumors. ICE^® molecules are created using Affimed’s ROCK^® platform, which generates customized molecules to utilize innate immune cells for tumor destruction. Several ICE^® molecules are currently undergoing clinical trials as both single and combination therapies. Based in Mannheim, Germany, Affimed is led by a team of biotechnology and pharmaceutical experts dedicated to preventing cancer from disrupting patients’ lives. More information about the company’s team, pipeline, and partners can be found at .

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements, identified by terms like “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions. These statements concern the listing and trading of Affimed’s common shares, among other things. Actual outcomes may significantly differ from those projected due to risks, uncertainties, and other factors detailed in the “Risk Factors” section of the company’s SEC filings. Therefore, undue reliance on these statements is discouraged, and Affimed is not obligated to update them, even if new information arises.

Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102

Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail:

“`